Appl Microbiol Biotechnol
Applied Microbiology and Biotechnology
0175-7598
1432-0614
Springer-Verlag
Berlin/Heidelberg


2039825
17704915
1142
10.1007/s00253-007-1142-2
Mini-Review


Properties, production, and applications of camelid single-domain antibody fragments

Harmsen
M. M.

+31-32-238436
+31-32-238961
michiel.harmsen@wur.nl

1

De Haard
H. J.

2

1
Institute for Animal Science and Health (ID-Lelystad) of Wageningen University and Research Centre, Edelhertweg 15, 8219 PH Lelystad, The Netherlands 
2
Ablynx N.V., Technologiepark 4, 9052 Zwijnaarde, Belgium 

18
8
2007

11
2007

77
1
13
22
13
6
2007

25
7
2007

30
7
2007


© Springer-Verlag 2007

Camelids produce functional antibodies devoid of light chains of which the single N-terminal domain is fully capable of antigen binding. These single-domain antibody fragments (VHHs or Nanobodies®) have several advantages for biotechnological applications. They are well expressed in microorganisms and have a high stability and solubility. Furthermore, they are well suited for construction of larger molecules and selection systems such as phage, yeast, or ribosome display. This minireview offers an overview of (1) their properties as compared to conventional antibodies, (2) their production in microorganisms, with a focus on yeasts, and (3) their therapeutic applications.

Keywords
Single-domain
Microbial production
Yeast
Glycosylation

issue-copyright-statement
© Springer-Verlag 2007




Introduction
1
Fig. 1
a
b
VH
VL
shaded dark gray
light gray
CH
CL
hatched spheres





1964
1967
1989
2002
1
a). Their production in microbial cells is often cumbersome, especially when producing multivalent formats, because of the requirement for domain association.
1993
1
1995
1997
2000a
2002
2003
2006
2006
2001
2006
).

Properties
1993
1994
1997
2000
1996
2001
1996
2004
2001
2005
).
2002
2001a
2004
2005a
2007
2000
2002
2001
1988
1994
2000
).
1997
2000
2000
1994
1996
). A particular subfamily of llama VHHs (VHH3) also contains an extended CDR3 that is stabilized by an additional disulfide bond with a cysteine at position 50 in FR2. However, VHHs of this subfamily are rarely isolated, and most llama VHHs have CDR3 loops similar in length to those found in human VHs.
1
Table 1
Advantages of camelid single-domain antibody fragments as compared to conventional antibody fragments

Advantage
Molecular basis


Facile genetic manipulation
Single-domain nature

Increased functional size of immune libraries
No decrease in library size because of reshuffling of VL and VH domains

Facile production of multivalent formats
More flexible linker design and no mispairing of VL and VH domains

Facile production of oligoclonal preparations from single cells
No mispairing of VL and VH domains

High physicochemical stability
Efficient refolding due to increased hydrophilicity and single-domain nature

High solubility
Increased hydrophilicity

Recognition of hidden antigenic sites
Small size and extended flexible CDR3

Rapid tissue penetration, fast clearance
Small size

Well expressed
Efficient folding due to increased hydrophilicity and single-domain nature



See text for references



2000
2005b
1
1990
1993
2006
2007
).
2002
). Because of regulatory requirements, such oligoclonals are preferentially produced from single cells. Again, VHHs are predicted to be more suitable for single-cell production of oligoclonals because of the absence of domain mispairing, although this is yet to be demonstrated experimentally.
1999
1999
2001
2001
2002
2002
1995
1996
2005
2003
). Furthermore, refolding of VHHs only requires domain refolding, whereas conventional antibodies also require association of VH and VL domains.
1998
2006
2004
1996
2006
2003
2002
2001
2000
2003
2007
2007
2001
K
D
2004
2006
2006
2002
).
2004
2006
2002
2005a
) is a disadvantage.

Production in microorganisms
Escherichia coli
2005
2006
E. coli
E. coli
2005
). Using eukaryotic microbial hosts, antibody fragments are generally produced by targeting to the secretory pathway. This enables efficient disulfide bond formation, addition of N-linked oligosaccharide, and secretion of soluble, correctly folded product to the culture medium.
E. coli
1997
2005
2005
2004
Saccharomyces cerevisiae
2000
2002
2002
Pichia pastoris
2006
2000
2005a
2006
2006
).
2000
2005b
2007
2000
E. coli
2002
E. coli
1995
2006
E. coli
1997
2000
2005b
2000b
2006
E. coli
2004
2007
).
2005
2007
P. pastoris
2006
).
1
2001b
2005a
2006
2007
2001b
E. coli
2004
1
b).
1997
2003
P. pastoris
2006
2006
).

Therapeutic applications
2005
2003
2004
2005
2
Table 2
Examples of therapeutic applications of camelid VHHs

Disease
Pathogen
Target antigen
VHH valency for disease target
Additional fusion partner
Reference


Sleeping sickness
Trypanosomes
VSG oligomannose
Monovalent
Apolipoprotein L-I
2006


Infant diarrhea
Rotavirus
Unknown
Monovalent
None
2006


Infant diarrhea
Rotavirus
Unknown
Monovalent
Lactobacillus
 cell-surface anchor
2006


Piglet diarrhea
E. coli

F4 fimbriae
Monovalent
None
2006


Caries
S. mutans

I/II adhesion
Monovalent
None
2006


FMD
FMD virus
VP1
Monovalent
PEG
2007


Sepsis
N. meningitidis

LPS
Monovalent
None
2006


Cancer
–
CEA
Monovalent
β-Lactamase
2004


Cancer
–
EGF receptor
Bivalent
Anti-albumin VHH
2007


Rheumatoid arthritis
–
TNFα
Bivalent
Anti-albumin VHH
2006


Brain disorders
–
α (2,3)-Sialoglycoprotein
Monovalent
None
2002


Neurodegenerative diseases
–
Bax
Monovalent
None
2006






2002
2003
E. coli
2005b
2006
2006
2006
2006
Streptococcus mutans
2006
). Because these VHHs should function in the oral cavity, the low level of protection cannot be due to proteolytic VHH degradation within the gastrointestinal tract.
2006
2007
2005a
2007
2007
).
2006
2004
2007
2007
2006
2006
).
2002
2006
2004
2006
) could also be applied to VHHs. Alternatively, immunogenicity could be reduced by the use of conventional-like VHHs, which have an even higher structural homology to conventional VH domains.
2002
2006
2006
2006
).

Conclusions
http://www.ablynx.com
).


References
Alvarez-Rueda
N

Behar
G

Ferre
V

Pugniere
M

Roquet
F

Gastinel
L

Jacquot
C

Aubry
J

Baty
D

Barbet
J

Birkle
S


Generation of llama single-domain antibodies against methotrexate, a prototypical hapten
Mol Immunol
2007
44
1680
1690
10.1016/j.molimm.2006.08.007

17011035


Arbabi-Ghahroudi
M

Desmyter
A

Wyns
L

Hamers
R

Muyldermans
S


Selection and identification of single domain antibody fragments from camel heavy-chain antibodies
FEBS Lett
1997
414
521
526
10.1016/S0014-5793(97)01062-4

9323027


Arbabi-Ghahroudi
M

Tanha
J

MacKenzie
R


Prokaryotic expression of antibodies
Cancer Metastasis Rev
2005
24
501
519
10.1007/s10555-005-6193-1

16408159


Baral
TN

Magez
S

Stijlemans
B

Conrath
K

Vanhollebeke
B

Pays
E

Muyldermans
S

Baetselier
P


Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor
Nat Med
2006
12
580
584
10.1038/nm1395

16604085


Bond
CJ

Marsters
JC

Sidhu
SS


Contributions of CDR3 to VHH domain stability and the design of monobody scaffolds for naive antibody libraries
J Mol Biol
2003
332
643
655
10.1016/S0022-2836(03)00967-7

12963373


Conrath
KE

Lauwereys
M

Galleni
M

Matagne
A

Frere
JM

Kinne
J

Wyns
L

Muyldermans
S


Beta-lactamase inhibitors derived from single-domain antibody fragments elicited in the camelidae
Antimicrob Agents Chemother
2001
45
2807
2812
10.1128/AAC.45.10.2807-2812.2001

11557473


Conrath
KE

Lauwereys
M

Wyns
L

Muyldermans
S


Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs
J Biol Chem
2001
276
7346
7350
10.1074/jbc.M007734200

11053416


Conrath
KE

Vincke
C

Stijlemans
B

Schymkowitz
J

Decanniere
K

Wyns
L

Muyldermans
S

Loris
R


Antigen binding and solubility effects upon the veneering of a camel VHH in framework-2 to mimic a VH
J Mol Biol
2005
350
112
125
10.1016/j.jmb.2005.04.050

15913651


Coppieters
K

Dreier
T

Silence
K

Haard
H

Lauwereys
M

Casteels
P

Beirnaert
E

Jonckheere
H

Wiele
C

Staelens
L

Hostens
J

Revets
H

Remaut
E

Elewaut
D

Rottiers
P


Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis
Arthritis Rheum
2006
54
1856
1866
10.1002/art.21827

16736523


Cortez-Retamozo
V

Lauwereys
M

Hassanzadeh Gh
G

Gobert
M

Conrath
K

Muyldermans
S

Baetselier
P

Revets
H


Efficient tumor targeting by single-domain antibody fragments of camels
Int J Cancer
2002
98
456
462
10.1002/ijc.10212

11920600


Cortez-Retamozo
V

Backmann
N

Senter
PD

Wernery
U

Baetselier
P

Muyldermans
S

Revets
H


Efficient cancer therapy with a nanobody-based conjugate
Cancer Res
2004
64
2853
2857
10.1158/0008-5472.CAN-03-3935

15087403


Davies
J

Riechmann
L


Antibody VH domains as small recognition units
Biotechnology (NY)
1995
13
475
479
10.1038/nbt0595-475

Davies J, Riechmann L (1995) Antibody VH domains as small recognition units. Biotechnology (NY) 13:475–479 

Davies
J

Riechmann
L


Single antibody domains as small recognition units: design and in vitro antigen selection of camelized, human VH domains with improved protein stability
Protein Eng
1996
9
531
537
10.1093/protein/9.6.531

8862554


Genst
E

Silence
K

Decanniere
K

Conrath
K

Loris
R

Kinne
J

Muyldermans
S

Wyns
L


Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies
Proc Natl Acad Sci USA
2006
103
4586
4591
10.1073/pnas.0505379103

16537393


Desmyter
A

Transue
TR

Ghahroudi
MA

Thi
MH

Poortmans
F

Hamers
R

Muyldermans
S

Wyns
L


Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme
Nat Struct Biol
1996
3
803
811
10.1038/nsb0996-803

8784355


Desmyter
A

Decanniere
K

Muyldermans
S

Wyns
L


Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody
J Biol Chem
2001
276
26285
26290
10.1074/jbc.M102107200

11342547


Dolk
E

Vaart
M

Lutje Hulsik
D

Vriend
G

Haard
H

Spinelli
S

Cambillau
C

Frenken
L

Verrips
T


Isolation of llama antibody fragments for prevention of dandruff by phage display in shampoo
Appl Environ Microbiol
2005
71
442
450
10.1128/AEM.71.1.442-450.2005

15640220


Dufner
P

Jermutus
L

Minter
RR


Harnessing phage and ribosome display for antibody optimisation
Trends Biotechnol
2006
24
523
529

17000017


Dumoulin
M

Conrath
K

Meirhaeghe
A

Meersman
F

Heremans
K

Frenken
LG

Muyldermans
S

Wyns
L

Matagne
A


Single-domain antibody fragments with high conformational stability
Protein Sci
2002
11
500
515
10.1110/ps.34602

11847273


Dumoulin
M

Last
AM

Desmyter
A

Decanniere
K

Canet
D

Larsson
G

Spencer
A

Archer
DB

Sasse
J

Muyldermans
S

Wyns
L

Redfield
C

Matagne
A

Robinson
CV

Dobson
CM


A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme
Nature
2003
424
783
788
10.1038/nature01870

12917687


Khattabi
M

Adams
H

Heezius
E

Hermans
P

Detmers
F

Maassen
B

Ley
P

Tommassen
J

Verrips
T

Stam
J


Llama single-chain antibody that blocks lipopolysaccharide binding and signaling: prospects for therapeutic applications
Clin Vaccine Immunol
2006
13
1079
1086
10.1128/CVI.00107-06

16928888


Estell
D


Adapting industry practices for the rapid, large-scale manufacture of pharmaceutical proteins
Bridge
2006
36
39
44

Estell D (2006) Adapting industry practices for the rapid, large-scale manufacture of pharmaceutical proteins. Bridge 36:39–44 

Ewert
S

Cambillau
C

Conrath
K

Pluckthun
A


Biophysical properties of camelid V(HH) domains compared to those of human V(H)3 domains
Biochemistry
2002
41
3628
3636
10.1021/bi011239a

11888279


Frenken
LGJ

Linden
RH

Hermans
PW

Bos
JW

Ruuls
RC

Geus
B

Verrips
CT


Saccharomyces cerevisiae

J Biotechnol
2000
78
11
21
10.1016/S0168-1656(99)00228-X

10702907


Gerngross
TU


Advances in the production of human therapeutic proteins in yeasts and filamentous fungi
Nat Biotechnol
2004
22
1409
1414
10.1038/nbt1028

15529166


Glockshuber
R

Malia
M

Pfitzinger
I

Pluckthun
A


A comparison of strategies to stabilize immunoglobulin Fv-fragments
Biochemistry
1990
29
1362
1367
10.1021/bi00458a002

2110478


Goldman
ER

Anderson
GP

Liu
JL

Delehanty
JB

Sherwood
LJ

Osborn
LE

Cummins
LB

Hayhurst
A


Facile generation of heat-stable antiviral and antitoxin single domain antibodies from a semisynthetic llama library
Anal Chem
2006
78
8245
8255
10.1021/ac0610053

17165813


Greenberg
AS

Avila
D

Hughes
M

Hughes
A

McKinney
EC

Flajnik
MF


A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks
Nature
1995
374
168
173
10.1038/374168a0

7877689


Gueorguieva
D

Li
S

Walsh
N

Mukerji
A

Tanha
J

Pandey
S


Identification of single-domain, Bax-specific intrabodies that confer resistance to mammalian cells against oxidative-stress-induced apoptosis
FASEB J
2006
20
2636
2638
10.1096/fj.06-6306fje

17060401


Hamers-Casterman
C

Atarhouch
T

Muyldermans
S

Robinson
G

Hamers
C

Songa
EB

Bendahman
N

Hamers
R


Naturally occurring antibodies devoid of light chains
Nature
1993
363
446
448
10.1038/363446a0

8502296


Hamilton
SR

Davidson
RC

Sethuraman
N

Nett
JH

Jiang
Y

Rios
S

Bobrowicz
P

Stadheim
TA

Li
H

Choi
BK

Hopkins
D

Wischnewski
H

Roser
J

Mitchell
T

Strawbridge
RR

Hoopes
J

Wildt
S

Gerngross
TU


Humanization of yeast to produce complex terminally sialylated glycoproteins
Science
2006
313
1441
1443
10.1126/science.1130256

16960007


Harmsen
MM

Ruuls
RC

Nijman
IJ

Niewold
TA

Frenken
LGJ

Geus
B


Llama heavy-chain V regions consist of at least four distinct subfamilies revealing novel sequence features
Mol Immunol
2000
37
579
590
10.1016/S0161-5890(00)00081-X

11163394


Harmsen
MM

Solt
CB

Fijten
HPD

Setten
MC


Prolonged in vivo residence times of llama single-domain antibody fragments in pigs by binding to porcine immunoglobulins
Vaccine
2005
23
4926
4934
10.1016/j.vaccine.2005.05.017

15992972


Harmsen
MM

Solt
CB

Hoogendoorn
A

Zijderveld
FG

Niewold
TA

Meulen
J


Escherichia coli F4 fimbriae specific llama single-domain antibody fragments effectively inhibit bacterial adhesion in vitro but poorly protect against diarrhoea
Vet Microbiol
2005
111
89
98
10.1016/j.vetmic.2005.09.005

16221532


Harmsen
MM

Solt
CB

Zijderveld-van Bemmel
AM

Niewold
TA

Zijderveld
FG


Selection and optimization of proteolytically stable llama single-domain antibody fragments for oral immunotherapy
Appl Microbiol Biotechnol
2006
72
544
551
10.1007/s00253-005-0300-7

16450109


Harmsen
MM

Solt
CB

Fijten
HPD

Keulen
L

Rosalia
RA

Weerdmeester
K

Cornelissen
AHM

Bruin
MGM

Eblé
PL

Dekker
A


Passive immunization of guinea-pigs with llama single-domain antibody fragments against foot-and-mouth disease
Vet Microbiol
2007
120
193
206
10.1016/j.vetmic.2006.10.029

17127019


Harrison
RA

Hasson
SS

Harmsen
M

Laing
GD

Conrath
K

Theakston
RD


Neutralisation of venom-induced haemorrhage by IgG from camels and llamas immunised with viper venom and also by endogenous, non-IgG components in camelid sera
Toxicon
2006
47
364
368
10.1016/j.toxicon.2005.10.017

16359717


Hermeling
S

Crommelin
DJ

Schellekens
H

Jiskoot
W


Structure–immunogenicity relationships of therapeutic proteins
Pharm Res
2004
21
897
903
10.1023/B:PHAM.0000029275.41323.a6

15212151


Holliger
P

Hudson
PJ


Engineered antibody fragments and the rise of single domains
Nat Biotechnol
2005
23
1126
1136
10.1038/nbt1142

16151406


Holliger
P

Wing
M

Pound
JD

Bohlen
H

Winter
G


Retargeting serum immunoglobulin with bispecific diabodies
Nat Biotechnol
1997
15
632
636
10.1038/nbt0797-632

9219264


Janssens
R

Dekker
S

Hendriks
RW

Panayotou
G

Remoortere
A

San
JK

Grosveld
F

Drabek
D


Generation of heavy-chain-only antibodies in mice
Proc Natl Acad Sci USA
2006
103
15130
15135
10.1073/pnas.0601108103

17015837


Jespers
L

Schon
O

Famm
K

Winter
G


Aggregation-resistant domain antibodies selected on phage by heat denaturation
Nat Biotechnol
2004
22
1161
1165
10.1038/nbt1000

15300256


Joosten
V

Roelofs
MS

Dries
N

Goosen
T

Verrips
CT

Hondel
CA

Lokman
BC


Aspergillus awamori
Arthromyces ramosus
 peroxidase (ARP)
J Biotechnol
2005
120
347
359
10.1016/j.jbiotec.2005.06.034

16169108


Kruger
C

Hultberg
A

Marcotte
H

Hermans
P

Bezemer
S

Frenken
LG

Hammarstrom
L


Streptococcus mutans
 on the development of dental caries
Appl Microbiol Biotechnol
2006
72
732
737
10.1007/s00253-006-0347-0

16636830


Lange
IG

Daxenberger
A

Meyer
HH


Lama glama
—evaluation of the binding capacity of different IgG subtypes in ELISAs for clenbuterol and BSA
Vet Immunol Immunopathol
2001
83
1
9
10.1016/S0165-2427(01)00376-2

11604157


Lauwereys
M

Arbabi Ghahroudi
M

Desmyter
A

Kinne
J

Holzer
W

Genst
E

Wyns
L

Muyldermans
S


Potent enzyme inhibitors derived from dromedary heavy-chain antibodies
Embo J
1998
17
3512
3520
10.1093/emboj/17.13.3512

9649422


Lesk
AM

Chothia
C


Elbow motion in the immunoglobulins involves a molecular ball-and-socket joint
Nature
1988
335
188
190
10.1038/335188a0

3412476


Muruganandam
A

Tanha
J

Narang
S

Stanimirovic
D


Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium
Faseb J
2002
16
240
242

11772942


Muyldermans
S


Single domain camel antibodies: current status
J Biotechnol
2001
74
277
302

11526908


Muyldermans
S

Atarhouch
T

Saldanha
J

Barbosa
JA

Hamers
R


Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains
Protein Eng
1994
7
1129
35
10.1093/protein/7.9.1129

7831284


Muyldermans
S

Cambillau
C

Wyns
L


Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains
Trends Biochem Sci
2001
26
230
235
10.1016/S0968-0004(01)01790-X

11295555


Nguyen
VK

Hamers
R

Wyns
L

Muyldermans
S


Camel heavy-chain antibodies: diverse germline V(H)H and specific mechanisms enlarge the antigen-binding repertoire
Embo J
2000
19
921
930
10.1093/emboj/19.5.921

10698934


Nguyen
VK

Zou
X

Lauwereys
M

Brys
L

Bruggemann
M

Muyldermans
S


Heavy-chain only antibodies derived from dromedary are secreted and displayed by mouse B cells
Immunology
2003
109
93
101
10.1046/j.1365-2567.2003.01633.x

12709022


Nieba
L

Honegger
A

Krebber
C

Pluckthun
A


Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved in vivo folding and physical characterization of an engineered scFv fragment
Protein Eng
1997
10
435
444
10.1093/protein/10.4.435

9194169


Nowakowski
A

Wang
C

Powers
DB

Amersdorfer
P

Smith
TJ

Montgomery
VA

Sheridan
R

Blake
R

Smith
LA

Marks
JD


Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody
Proc Natl Acad Sci USA
2002
99
11346
11350
10.1073/pnas.172229899

12177434


Olichon
A

Schweizer
D

Muyldermans
S

Marco
A


Heating as a rapid purification method for recovering correctly-folded thermotolerant VH and VHH domains
BMC Biotechnol
2007
7
7
10.1186/1472-6750-7-7

17257422


Pant
N

Hultberg
A

Zhao
Y

Svensson
L

Pan-Hammarstrom
Q

Johansen
K

Pouwels
PH

Ruggeri
FM

Hermans
P

Frenken
L

Boren
T

Marcotte
H

Hammarstrom
L


Lactobacilli expressing variable domain of llama heavy-chain antibody fragments (lactobodies) confer protection against rotavirus-induced diarrhea
J Infect Dis
2006
194
1580
1588
10.1086/508747

17083044


Perez
JM

Renisio
JG

Prompers
JJ

Platerink
CJ

Cambillau
C

Darbon
H

Frenken
LG


Thermal unfolding of a llama antibody fragment: a two-state reversible process
Biochemistry
2001
40
74
83
10.1021/bi0009082

11141058


Pleschberger
M

Saerens
D

Weigert
S

Sleytr
UB

Muyldermans
S

Sara
M

Egelseer
EM


An S-layer heavy chain camel antibody fusion protein for generation of a nanopatterned sensing layer to detect the prostate-specific antigen by surface plasmon resonance technology
Bioconjug Chem
2004
15
664
671
10.1021/bc049964w

15149195


Presta
LG


Engineering of therapeutic antibodies to minimize immunogenicity and optimize function
Adv Drug Deliv Rev
2006
58
640
656
10.1016/j.addr.2006.01.026

16904789


Rahbarizadeh
F

Rasaee
MJ

Forouzandeh-Moghadam
M

Allameh
AA


High expression and purification of the recombinant camelid anti-MUC1 single domain antibodies in Escherichia coli
Protein Expr Purif
2005
44
32
38
10.1016/j.pep.2005.04.008

15922625


Rahbarizadeh
F

Rasaee
MJ

Forouzandeh
M

Allameh
AA


Pichia pastoris

Mol Immunol
2006
43
426
435
10.1016/j.molimm.2005.03.003

16337485


Reichert
JM

Valge-Archer
VE


Development trends for monoclonal antibody cancer therapeutics
Nat Rev Drug Discov
2007
6
349
356
10.1038/nrd2241

17431406


Revets
H

Baetselier
P

Muyldermans
S


Nanobodies as novel agents for cancer therapy
Expert Opin Biol Ther
2005
5
111
124
10.1517/14712598.5.1.111

15709914


Roovers
RC

Laeremans
T

Huang
L

Taeye
S

Verkleij
AJ

Revets
H

Haard
HJ

Bergen en Henegouwen
PM


Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies
Cancer Immunol Immunother
2007
56
303
317
10.1007/s00262-006-0180-4

16738850


Rothbauer
U

Zolghadr
K

Tillib
S

Nowak
D

Schermelleh
L

Gahl
A

Backmann
N

Conrath
K

Muyldermans
S

Cardoso
MC

Leonhardt
H


Targeting and tracing antigens in live cells with fluorescent nanobodies
Nat Methods
2006
3
887
889
10.1038/nmeth953

17060912


Saerens
D

Kinne
J

Bosmans
E

Wernery
U

Muyldermans
S

Conrath
K


Single domain antibodies derived from dromedary lymph node and peripheral blood lymphocytes sensing conformational variants of prostate-specific antigen
J Biol Chem
2004
279
51965
51972
10.1074/jbc.M409292200

15459193


Sagt
CM

Kleizen
B

Verwaal
R

Jong
MD

Muller
WH

Smits
A

Visser
C

Boonstra
J

Verkleij
AJ

Verrips
CT


Introduction of an N-glycosylation site increases secretion of heterologous proteins in yeasts
Appl Environ Microbiol
2000
66
4940
4944
10.1128/AEM.66.11.4940-4944.2000

11055947


Sethuraman
N

Stadheim
TA


Challenges in therapeutic glycoprotein production
Curr Opin Biotechnol
2006
17
341
346
10.1016/j.copbio.2006.06.010

16828275


Simmons
DP

Abregu
FA

Krishnan
UV

Proll
DF

Streltsov
VA

Doughty
L

Hattarki
MK

Nuttall
SD


Dimerisation strategies for shark IgNAR single domain antibody fragments
J Immunol Methods
2006
315
171
184
10.1016/j.jim.2006.07.019

16962608


Spinelli
S

Frenken
L

Bourgeois
D

Ron
L

Bos
W

Verrips
T

Anguille
C

Cambillau
C

Tegoni
M


The crystal structure of a llama heavy chain variable domain
Nat Struct Biol
1996
3
752
757
10.1038/nsb0996-752

8784347


Spinelli
S

Frenken
LG

Hermans
P

Verrips
T

Brown
K

Tegoni
M

Cambillau
C


Camelid heavy-chain variable domains provide efficient combining sites to haptens
Biochemistry
2000
39
1217
1222
10.1021/bi991830w

10684599


Stijlemans
B

Conrath
K

Cortez-Retamozo
V

Xong
H

Wyns
L

Senter
P

Revets
H

Baetselier
P

Muyldermans
S

Magez
S


Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm
J Biol Chem
2004
279
1256
1261
10.1074/jbc.M307341200

14527957


Streltsov
VA

Varghese
JN

Carmichael
JA

Irving
RA

Hudson
PJ

Nuttall
SD


Structural evidence for evolution of shark Ig new antigen receptor variable domain antibodies from a cell-surface receptor
Proc Natl Acad Sci USA
2004
101
12444
12449
10.1073/pnas.0403509101

15304650


Sundberg
EJ

Mariuzza
RA


Molecular recognition in antibody-antigen complexes
Adv Protein Chem
2002
61
119
160

12461823


Tanha
J

Dubuc
G

Hirama
T

Narang
SA

MacKenzie
CR


Selection by phage display of llama conventional V(H) fragments with heavy chain antibody V(H)H properties
J Immunol Methods
2002
263
97
109
10.1016/S0022-1759(02)00027-3

12009207


Thomassen
YE

Meijer
W

Sierkstra
L

Verrips
CT


Saccharomyces cerevisiae

Enzyme Microb Technol
2002
30
273
278
10.1016/S0141-0229(01)00497-5

Thomassen YE, Meijer W, Sierkstra L, Verrips CT (2002) Large-scale production of VHH antibody fragments by Saccharomyces cerevisiae. Enzyme Microb Technol 30:273–278 

Thomassen
YE

Verkleij
AJ

Boonstra
J

Verrips
CT


Saccharomyces cerevisiae
 is correlated with growth rate, independent of nutrient limitation
J Biotechnol
2005
118
270
277
10.1016/j.jbiotec.2005.05.010

15979755


Utsumi
S

Karush
F


The subunits of purified rabbit antibody
Biochemistry
1964
3
1329
1338
10.1021/bi00897a024

14229677


Laar
T

Visser
C

Holster
M

Lopez
CG

Kreuning
D

Sierkstra
L

Lindner
N

Verrips
T


Saccharomyces cerevisiae
 growing on ethanol as sole carbon source
Biotechnol Bioeng
2007
96
483
494
10.1002/bit.21150

16948170


Linden
RH

Frenken
LG

Geus
B

Harmsen
MM

Ruuls
RC

Stok
W

Ron
L

Wilson
S

Davis
P

Verrips
CT


Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies
Biochim Biophys Acta
1999
1431
37
46

10209277


Linden
R

Geus
B

Stok
W

Bos
W

Wassenaar
D

Verrips
T

Frenken
L


Lama glama

J Immunol Methods
2000
240
185
195
10.1016/S0022-1759(00)00188-5

10854612


Linden
RH

Geus
B

Frenken
GJ

Peters
H

Verrips
CT


Improved production and function of llama heavy chain antibody fragments by molecular evolution
J Biotechnol
2000
80
261
270
10.1016/S0168-1656(00)00274-1

10949316


Vaart
JM


O'Brien
PM

Aitken
R


Expression of VHH antibody fragments in Saccharomyces cerevisiae
Methods in molecular biology, vol 178. Antibody phage display: methods and protocols
2002
Totowa, NJ
Humana
359
366

Van der Vaart JM (2002) Expression of VHH antibody fragments in Saccharomyces cerevisiae. In: O'Brien PM, Aitken R (eds) Methods in molecular biology, vol 178. Antibody phage display: methods and protocols. Humana, Totowa, NJ, pp 359–366 

Vaart
JM

Pant
N

Wolvers
D

Bezemer
S

Hermans
PW

Bellamy
K

Sarker
SA

Logt
CP

Svensson
L

Verrips
CT

Hammarstrom
L

Klinken
BJ


Reduction in morbidity of rotavirus induced diarrhoea in mice by yeast produced monovalent llama-derived antibody fragments
Vaccine
2006
24
4130
4137
10.1016/j.vaccine.2006.02.045

16616802


Verheesen
P

ten Haaft
MR

Lindner
N

Verrips
CT

Haard
JJ


Beneficial properties of single-domain antibody fragments for application in immunoaffinity purification and immuno-perfusion chromatography
Biochim Biophys Acta
2003
1624
21
28

14642809


Verheesen
P

Roussis
A

Haard
HJ

Groot
AJ

Stam
JC

den Dunnen
JT

Frants
RR

Verkleij
AJ

Verrips
CT

Maarel
SM


Reliable and controllable antibody fragment selections from camelid non-immune libraries for target validation
Biochim Biophys Acta
2006
1764
1307
1319

16872921


Vu
KB

Ghahroudi
MA

Wyns
L

Muyldermans
S


Comparison of llama VH sequences from conventional and heavy chain antibodies
Mol Immunol
1997
34
1121
1131
10.1016/S0161-5890(97)00146-6

9566760


Ward
ES

Gussow
D

Griffiths
AD

Jones
PT

Winter
G


Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli
Nature
1989
341
544
546
10.1038/341544a0

2677748


Whitlow
M

Bell
BA

Feng
SL

Filpula
D

Hardman
KD

Hubert
SL

Rollence
ML

Wood
JF

Schott
ME

Milenic
DE



An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability
Protein Eng
1993
6
989
995
10.1093/protein/6.8.989

8309948


Yau
KY

Groves
MA

Li
S

Sheedy
C

Lee
H

Tanha
J

MacKenzie
CR

Jermutus
L

Hall
JC


Selection of hapten-specific single-domain antibodies from a non-immunized llama ribosome display library
J Immunol Methods
2003
281
161
175
10.1016/j.jim.2003.07.011

14580890


Yoo
TJ

Roholt
OA

Pressman
D


Specific binding activity of isolated light chains of antibodies
Science
1967
157
707
709
10.1126/science.157.3789.707

6028046


Zhang
J

Tanha
J

Hirama
T

Khieu
NH

To
R

Tong-Sevinc
H

Stone
E

Brisson
JR

MacKenzie
CR


Pentamerization of single-domain antibodies from phage libraries: a novel strategy for the rapid generation of high-avidity antibody reagents
J Mol Biol
2004
335
49
56
10.1016/j.jmb.2003.09.034

14659739


Zwick
MB

Parren
PW

Saphire
EO

Church
S

Wang
M

Scott
JK

Dawson
PE

Wilson
IA

Burton
DR


Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120
J Virol
2003
77
5863
5876
10.1128/JVI.77.10.5863-5876.2003

12719580





